Lactobacillus crispatus (KBLP-002) / KoBioLabs, Shanghai Pharma - LARVOL DELTA

Lactobacillus crispatus KBL693 alleviates atopic dermatitis symptoms through immune modulation. (PubMed, J Microbiol) - "In addition to downregulating these AD-associated immune responses, KBL693 promoted regulatory T cell (Treg) expansion in mesenteric lymph nodes, indicating its potential to restore immune balance. Collectively, these findings highlight the therapeutic potential of KBL693 for AD through enhancement of Tregs and suppression of type 2 immune responses."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immune Modulation • Immunology • IL13 • IL4 • IL5

KoBioLabs, exporting 120 billion won worth of technology for immune disease treatment materials to China [Google translation] (MBN) - "KoBioLabs...exports about 100 million won technology to SPH SINE, a subsidiary of Shanghai Pharma, China, which is an immune disease treatment material, 'KBL697' and 'KBL693'. It was announced on the 28th that it had signed a contract worth 7 million dollars (about 125.3 billion won). KoBioLabs will receive a down payment of $2.5 million (about KRW 2.9 billion) with no obligation to return, and milestones for each stage of clinical development, approval, and commercialization sequentially. Royalty is separate, and the contract term is 20 years after product release. Shin-Yi has secured the rights to develop and commercialize KBL697 and KBL693 in China, Hong Kong, Macao and Taiwan. The rights to other regions are reserved by KoBioLabs."

Licensing / partnership • Asthma • Atopic Dermatitis • Dermatology • Inflammatory Bowel Disease • Psoriasis • Respiratory Diseases • Ulcerative Colitis

Study of Multiple Ascending Dose of KBL693 in Healthy Participants (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: KoBioLabs; Recruiting ➔ Completed

Clinical • Trial completion • Asthma • Immunology • Respiratory Diseases

Study of Multiple Ascending Dose of KBL693 in Healthy Participants (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: KoBioLabs; Not yet recruiting ➔ Recruiting; Initiation date: Apr 2020 ➔ Aug 2020; Trial primary completion date: Jul 2020 ➔ Oct 2020

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Asthma • Respiratory Diseases

Study of Multiple Ascending Dose of KBL693 in Healthy Participants (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: KoBioLabs

Clinical • New P1 trial